BidaskClub lowered shares of Bruker (NASDAQ:BRKR) from a strong-buy rating to a buy rating in a research note issued to investors on Thursday, January 11th.
Other equities analysts also recently issued research reports about the stock. Zacks Investment Research downgraded shares of Bruker from a buy rating to a hold rating in a report on Tuesday, January 9th. BTIG Research started coverage on shares of Bruker in a research report on Friday, January 5th. They issued a buy rating and a $42.00 price objective for the company. Evercore ISI started coverage on shares of Bruker in a research report on Wednesday, January 3rd. They issued an in-line rating and a $36.00 price objective for the company. Cowen restated a hold rating and issued a $35.00 price objective on shares of Bruker in a research report on Thursday, December 21st. Finally, Morgan Stanley reiterated an equal weight rating and set a $35.00 target price on shares of Bruker in a report on Thursday, December 14th. Two analysts have rated the stock with a sell rating, ten have given a hold rating and five have issued a buy rating to the company. Bruker currently has a consensus rating of Hold and an average target price of $32.38.
Bruker (BRKR) traded down $0.27 during midday trading on Thursday, reaching $33.17. 431,988 shares of the company’s stock traded hands, compared to its average volume of 499,561. The stock has a market cap of $5,170.00, a PE ratio of 35.36, a PEG ratio of 2.61 and a beta of 1.05. Bruker has a fifty-two week low of $21.83 and a fifty-two week high of $36.53. The company has a quick ratio of 1.60, a current ratio of 2.60 and a debt-to-equity ratio of 0.65.
Large investors have recently made changes to their positions in the stock. Acrospire Investment Management LLC grew its stake in Bruker by 496.1% in the 2nd quarter. Acrospire Investment Management LLC now owns 3,827 shares of the medical research company’s stock valued at $110,000 after acquiring an additional 3,185 shares during the period. SG Americas Securities LLC purchased a new position in Bruker in the 2nd quarter valued at $111,000. Zions Bancorporation purchased a new position in Bruker in the 3rd quarter valued at $119,000. Bank of Montreal Can lifted its holdings in Bruker by 346.7% in the 4th quarter. Bank of Montreal Can now owns 3,708 shares of the medical research company’s stock valued at $128,000 after purchasing an additional 2,878 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Bruker by 11.3% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,599 shares of the medical research company’s stock worth $133,000 after acquiring an additional 467 shares during the period. 65.63% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/06/bruker-brkr-lowered-to-buy-at-bidaskclub.html.
Bruker Company Profile
Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.